Theravance Biopharma Presents Updates on Ampreloxetine
Theravance Biopharma, Inc. (NASDAQ: TBPH) is set to make significant presentations at the upcoming 36th International Symposium on the Autonomic Nervous System. This event, organized by the American Autonomic Society, will feature a robust clinical development program revolving around ampreloxetine, a potential first-in-class norepinephrine reuptake inhibitor aimed at treating neurogenic orthostatic hypotension (nOH) symptoms associated with multiple system atrophy (MSA).
Exciting Presentations Scheduled
The company has planned to deliver one platform presentation and three poster presentations across the symposium, which will take place from November 5-8, 2025. The platform will focus on the impressive results gathered from the previous REDWOOD trial, where ampreloxetine was observed to provide a durable symptomatic benefit in patients with MSA.
A Clinical Leader Speaks
Dr. Lucy Norcliffe-Kaufmann, the Executive Director of Clinical Science at Theravance Biopharma, emphasizes the excitement surrounding the symposium. "Our findings support the use of ampreloxetine not only as a treatment for nOH but also highlight its ability to enhance daily living activities for patients suffering from MSA," she shares. This reflects a pivotal moment in the development of treatment options for patients facing such debilitating conditions.
Platform Presentation Details
The key platform presentation is titled "Precision therapy with ampreloxetine for neurogenic orthostatic hypotension in multiple system atrophy." Dr. Norcliffe-Kaufmann will present this on Saturday, November 8, 2025, at 8:30 AM ET.
Posters Highlighting Critical Research
In addition to the platform presentation, the company will showcase three important posters on Thursday, November 6, during Poster Session II. The topics include:
- The impact of ampreloxetine on supine hypertension: an ambulatory blood pressure monitoring study. Presented by Dr. Norcliffe-Kaufmann.
- Retention strategies in rare disease clinical trials: a case study of symptomatic treatment for multiple system atrophy. Presented by Molly Szpyhulsky, MBA, BSN, RN.
- Enrollment strategies in a phase III trial for MSA-related nOH: insights from global investigators. Presented by Molly Szpyhulsky, MBA, BSN, RN.
Understanding Ampreloxetine
Ampreloxetine is an investigational drug designed to treat symptomatic nOH in patients with MSA. Its advantages include increased norepinephrine levels and positive effects on managing blood pressure. Previous studies have suggested that ampreloxetine not only improves symptoms but may also prevent an exacerbation of supine hypertension, making it a hopeful option for individuals battling this condition.
Phase 3 Studies of Ampreloxetine
The ongoing Phase 3 CYPRESS study aims to evaluate the efficacy and durability of ampreloxetine treatment among patients with MSA. The findings could lead to a New Drug Application (NDA) submission if the results are favorable.
The Challenge of MSA
Multiple System Atrophy is a progressive neurological disorder that deeply affects movement, balance, and autonomic functions. Among various symptoms, a significant one is a sudden drop in blood pressure upon standing, known as nOH. A substantial percentage of MSA patients experience nOH symptoms, underscoring the critical need for effective treatments.
The rare condition, defined by a notable decrease in blood pressure when standing, can severely impact patients' lives, causing dizziness, fainting, and fatigue. Addressing this condition effectively with solutions like ampreloxetine could change lives.
About Theravance Biopharma
Theravance Biopharma is dedicated to advancing treatments that genuinely improve patients' quality of life. Their work on YUPELRI®, approved for COPD maintenance treatment, exemplifies their commitment to medical innovation. The potential for ampreloxetine in treating nOH may set a new standard of care for those living with MSA.
Frequently Asked Questions
What is ampreloxetine?
Ampreloxetine is a selective norepinephrine reuptake inhibitor currently in development for treating symptomatic nOH in patients with multiple system atrophy.
When will the next presentations take place?
The next presentations regarding ampreloxetine are scheduled for the 36th International Symposium on the Autonomic Nervous System from November 5-8, 2025.
What is the goal of the CYPRESS study?
The CYPRESS study seeks to assess the efficacy and durability of ampreloxetine in treating nOH in patients with multiple system atrophy.
How does nOH affect patients with MSA?
nOH can cause a sudden drop in blood pressure upon standing, leading to symptoms like dizziness and fatigue, impairing daily activities significantly.
What is Theravance Biopharma's mission?
Theravance Biopharma is focused on developing medicines that positively impact patients' lives and creating value for their shareholders through innovative treatments.
